The dilemma of gastroenterological oncology: we know a lot but we still achieve too little.
Gieseler
F
F
I. Medizinische Klinik, Christian-Albrechts-Universität, Kiel, Germany. gieseler@hotmail.com
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3; D020169:Caspases / Q000187:drug effects*; D003110:Colonic Neoplasms / Q000517:prevention & control; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004792:Enzyme Precursors / Q000187:drug effects*; D019073:HT29 Cells / Q000187:drug effects*; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology*; D009842:Oligopeptides / Q000494:pharmacology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D015853:Cysteine Proteinase Inhibitors; D004792:Enzyme Precursors; D009842:Oligopeptides; C099158:acetyl-aspartyl-glutamyl-valyl-aspartal; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases; D007213:Indomethacin